Biogen plans to advance an experimental treatment for the neuromuscular disease spinal muscular atrophy, or SMA, into registrational studies following encouraging results from an early-stage trial.

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results – Investigational salanersen (ION306/BIIB115) developed using novel Ionis ...

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results ...